Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Glenn Saldanha, Managing Director, Glenmark Pharmaceuticals has been speaking about discovery research in India for more than a decade but his critics from bigger companies played down those efforts as high decibel talk, over-ambitious thoughts and a few even called them day dreaming moves. But five out-licensing deals in seven years with companies like Eli Lilly, Merck Serono and Sanofi-Aventis have transformed the way Glenmark Pharma is seen by the world today. Saldanha recalls the early days of his programs, the learning from his research partners and what his pipeline of drugs hold for the future in an exclusive interview with PharmAsia News' India bureau.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts